2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal Of Medicine 2021, 385: 1280-1291. PMID: 34587385, DOI: 10.1056/nejmoa2033617.Peer-Reviewed Original ResearchConceptsActive ulcerative colitisMaintenance therapyUlcerative colitisClinical remissionEnd pointClinical responseCohort 2Cohort 1Selective sphingosine-1-phosphate receptor modulatorSphingosine-1-phosphate receptor modulatorsElevated liver aminotransferase levelsKey secondary end pointLiver aminotransferase levelsPlacebo-controlled trialPrimary end pointSecondary end pointsPercentage of patientsDouble-blind mannerInflammatory bowel diseaseSame daily doseIncidence of infectionHistologic end pointsMayo scoreUnderwent randomizationAminotransferase levels
2017
Continued midazolam versus diphenhydramine in difficult-to-sedate patients: a randomized double-blind trial
Sachar H, Pichetshote N, Nandigam K, Vaidya K, Laine L. Continued midazolam versus diphenhydramine in difficult-to-sedate patients: a randomized double-blind trial. Gastrointestinal Endoscopy 2017, 87: 1297-1303. PMID: 28159539, PMCID: PMC5537051, DOI: 10.1016/j.gie.2017.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAnesthetics, IntravenousColonoscopyConscious SedationDiphenhydramineDouble-Blind MethodFemaleFentanylHumansHypnotics and SedativesIntention to Treat AnalysisMaleMidazolamMiddle AgedConceptsDouble-blind trialAdequate sedationStudy medicationModerate sedationAlertness/Sedation scoreAdequacy of sedationStudy medication dosePsychiatric medication useModified Observer's AssessmentMOAA/SAdditional medicationElective colonoscopyPrimary endpointOpioid combinationsOpioid useMedication useMore patientsSedation scoreSuch patientsMedication doseUsual dosesBenzodiazepine useCurrent guidelinesSedate patientsSedation